Patients with primary lung cancer detected using low-dose CT screening are at reduced risk of developing brain metastases after diagnosis, according to a study published in the Journal of Thoracic Oncology.
The researchers, led by Summer Han, PhD, from Stanford University School of Medicine in Palo Alto, Calif., used the National Lung Screening Trial data to identify 1502 participants who were diagnosed with lung cancer between 2002 to 2009 and have follow-up data for brain metastases.
Of 1,502 participants, 41.4% had lung cancer detected through LDCT screening versus 58.6% detected through other methods, for example, chest radiograph or incidental detection. Patients whose lung cancer was detected with LDCT screening had a significantly lower three-year incidence of brain metastases (6.5%) versus those without (11.9%), with a cause-specific hazard ratio (HR) of 0.53 (p = 0.001), adjusting for age at lung cancer diagnosis, stage, histology, and smoking status.
This significant reduction in brain metastases risk among patients with lung cancer detected through LDCT screening persisted in subgroups of participants with early-stage primary lung cancer (HR = 0.47, p = 0.002) and those who underwent surgery (HR = 0.37, p = 0.001).
To investigate potential explanations for an association between brain metastases risk and lung cancer detected by LDCT screening, the researchers explored LDCT imaging data using a subset of patients (n = 552) who were randomized to the LDCT arm and have LDCT imaging data available. The researchers then compared the characteristics of the nodules that were LDCT screen-detected versus those that were missed by LDCT screening among the patients who were interval detected in the LDCT screening arm.
Given the observed high rate of brain metastases among patients with lung cancer in stage I in NLST (32.4%), the research group further evaluated and compared the characteristics of the nodules of the patients who developed brain metastases (n = 12) versus those who did not develop brain metastases (n = 350) within the patients whose lung cancer was LDCT screen detected in stage I (n = 362).
“This reduction in risk for brain metastases among LDCT screen-detected lung cancer—which persisted in subgroup analyses of patients with early-stage lung cancer and those who underwent surgery for lung cancer—may not be fully explained by stage shift nor curative treatment for PLC,” says Han. “The reduction in brain metastases risk may be because of a potentially different tumor biology of the tumors detected by LDCT screening that are less aggressive and slow growing, which needs to be confirmed by further investigation.”
She continues, “To the best of our knowledge, our study presents the first effort investigating the potential impact of LDCT lung screening on subsequent risk of metastasis.” Han adds that using the NLST data with a long follow up period provided sufficient time to observe the development of brain metastases.